A phase II trial of CPT-11 [irinotecan] in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction incorporating pretreatment and posttreatment biopsies for evaluation of tumor thymidylate synthase, MIB-1, toposiomerase I, and p53
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2010
At a glance
- Drugs Irinotecan (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 26 Oct 2007 Status changed from in progress to completed.
- 17 Sep 2005 New trial record.